Results 31 to 40 of about 6,202 (185)

Evidence that GPVI is Expressed as a Mixture of Monomers and Dimers, and that the D2 Domain is not Essential for GPVI Activation [PDF]

open access: bronzeThrombosis and Haemostasis, 2021
Collagen has been proposed to bind to a unique epitope in dimeric glycoprotein VI (GPVI) and the number of GPVI dimers has been reported to increase upon platelet activation.
Joanne C. Clark   +14 more
openalex   +2 more sources

A key role for platelet GPVI in neutrophil recruitment, migration and NETosis in the early stages of acute lung injury.

open access: yesBlood, 2023
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are associated with high morbidity and mortality. Excessive neutrophil infiltration into the pulmonary airspace is the main cause for the acute inflammation and lung injury. Platelets
Philipp Burkard   +11 more
semanticscholar   +1 more source

Rac Inhibition Causes Impaired GPVI Signalling in Human Platelets through GPVI Shedding and Reduction in PLCγ2 Phosphorylation [PDF]

open access: goldInternational Journal of Molecular Sciences, 2022
Rac1 is a small Rho GTPase that is activated in platelets upon stimulation with various ligands, including collagen and thrombin, which are ligands for the glycoprotein VI (GPVI) receptor and the protease-activated receptors, respectively. Rac1-deficient
Raluca A. I. Neagoe   +5 more
openalex   +2 more sources

Perspective: Collagen induced platelet activation via the GPVI receptor as a primary target of colchicine in cardiovascular disease

open access: yesFrontiers in Cardiovascular Medicine, 2023
Colchicine has been demonstrated to reduce cardiovascular death, myocardial infarction (MI), ischemic stroke, and ischemia-driven coronary revascularization in people with coronary artery disease (CAD).
G. Pennings   +4 more
semanticscholar   +1 more source

Platelet Activation by Antisense Oligonucleotides (ASOs) in the Göttingen Minipig, including an Evaluation of Glycoprotein VI (GPVI) and Platelet Factor 4 (PF4) Ontogeny

open access: yesPharmaceutics, 2023
Antisense oligonucleotide (ASO) is a therapeutic modality that enables selective modulation of undruggable protein targets. However, dose- and sequence-dependent platelet count reductions have been reported in nonclinical studies and clinical trials. The
Allan Valenzuela   +6 more
semanticscholar   +1 more source

Absence of bleeding upon dual antiplatelet therapy in a patient with a immune GPVI deficiency

open access: yesPlatelets, 2021
Acquired deficiencies in platelet glycoprotein VI are rare and have not been found associated with other defects. Here we report the case of a 64-year old male patient presenting an immune GPVI deficiency associated to a mutation in the alpha-actinin ...
Stéphane Loyau Inserm   +5 more
doaj   +1 more source

Targeting GPVI with glenzocimab in COVID-19 patients: Results from a randomized clinical trial

open access: goldPLoS ONE
Background Glenzocimab is a novel antithrombotic agent which targets platelet glycoprotein VI (GPVI) and does not induce haemorrhage. SARS-CoV-2 triggers a prothrombotic state and lung injury whose mechanisms include coagulopathy, endothelial dysfunction,
Julien Pottecher   +14 more
openalex   +3 more sources

Association between endometriosis, infertility and autoimmune antiplatelet glycoprotein VI antibodies in two patients

open access: yesPlatelets, 2023
The association between endometriosis and autoimmune diseases is well known, however no acquired platelet function defect has been described so far. We describe the case of two patients with endometriosis associated with an antiplatelet glycoprotein VI ...
Stéphane Loyau   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy